TrialLeukemia & lymphoma2015

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.

Clive S Zent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.